Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study.

Abstract

ObjectivePatients with rheumatoid arthritis (RA) are at an increased risk of acquiring infections owing to immunologic dysfunction and use of potent immunomodulatory medications; however, few data are available on their risk of COVID‐19. We estimated the rate of COVID‐19 among RA participants and compared it with that of the general population.MethodsUsing the Health Improvement Network, we identified RA patients before February 2020 and followed them to September 2020. We calculated the rate of COVID‐19 among participants with RA and compared it with that of the general population using a Cox proportional hazards model, adjusting for potential confounders using overlap weighting of exposure score. We repeated the same analysis among participants with osteoarthritis, a nonautoimmune rheumatic disease, as a negative control exposure.ResultsWe identified 225 cases of suspected and confirmed COVID‐19 among 17,268 RA patients, and 14,234 cases among 1,616,600 participants in the general population (1.4 versus 0.9/1,000 person‐months), with the adjusted hazard ratio (HRadj) being 1.19 (95% confidence interval [95% CI] 1.04–1.36). Confirmed COVID‐19 cases developed in 46 RA participants and in 2,249 in the general population (0.3 versus 0.1/1,000 person‐months), with the HRadj being 1.42 (95% CI 1.01–1.95). No statistically significant difference was observed for suspected and confirmed (HR 1.00 [95% CI 0.93–1.07]) or confirmed (HR 1.08 [95% CI 0.92–1.27]) COVID‐19 rates between participants with osteoarthritis and the general population.ConclusionRA, but not osteoarthritis, was associated with an increased risk of COVID‐19. Our findings provide timely evidence to support recommendations that booster vaccines and priority access to anti–SARS–CoV‐2 monoclonal antibody treatments should be encouraged for RA patients.